Total Payments
$1.3M
2024 Payments
$179,948
Companies
82
Transactions
3,036
Medicare Patients
41,306
Medicare Billing
$2.4M
Payment Breakdown by Category
Other$1.1M (82.5%)
Consulting$65,969 (5.2%)
Food & Beverage$62,988 (4.9%)
Travel$55,187 (4.3%)
Research$39,508 (3.1%)
Education$199.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $982,870 | 541 | 76.8% |
| Consulting Fee | $65,969 | 41 | 5.2% |
| Food and Beverage | $62,988 | 1,885 | 4.9% |
| Travel and Lodging | $55,187 | 509 | 4.3% |
| Unspecified | $39,508 | 3 | 3.1% |
| Honoraria | $27,103 | 15 | 2.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $24,888 | 12 | 1.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $21,413 | 12 | 1.7% |
| Education | $199.75 | 18 | 0.0% |
Payments by Type
General
$1.2M
3,033 transactions
Research
$39,508
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $293,649 | 505 | $0 (2024) |
| Lilly USA, LLC | $265,961 | 431 | $0 (2024) |
| Amgen Inc. | $118,950 | 280 | $0 (2024) |
| Amarin Pharma Inc. | $104,491 | 195 | $0 (2023) |
| Abbott Laboratories | $99,843 | 171 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $74,446 | 149 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $49,337 | 107 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $48,223 | 53 | $0 (2022) |
| Kowa Pharmaceuticals America, Inc. | $32,955 | 63 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $32,728 | 116 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $179,948 | 406 | Lilly USA, LLC ($62,145) |
| 2023 | $130,540 | 350 | Lilly USA, LLC ($73,387) |
| 2022 | $175,737 | 352 | Lilly USA, LLC ($70,575) |
| 2021 | $82,805 | 266 | Novo Nordisk Inc ($37,719) |
| 2020 | $116,150 | 269 | Lilly USA, LLC ($33,998) |
| 2019 | $184,108 | 441 | Novo Nordisk Inc ($49,566) |
| 2018 | $195,682 | 468 | Novo Nordisk Inc ($48,546) |
| 2017 | $215,155 | 484 | Novo Nordisk Inc ($51,626) |
All Payment Transactions
3,036 individual payment records from CMS Open Payments — Page 1 of 122
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Bone Health | ||||||
| 12/18/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $2,286.00 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Travel and Lodging | Cash or cash equivalent | $74.20 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $980.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Amphastar Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.28 | General |
| 12/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Obesity | ||||||
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,273.00 | General |
| Category: Cardio-renal | ||||||
| 12/13/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $104.52 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $30.94 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/10/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Honoraria | Cash or cash equivalent | $2,940.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $38.46 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardio-renal | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Cardio-renal | ||||||
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $2,286.00 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Travel and Lodging | Cash or cash equivalent | $34.48 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $20.42 | General |
| 12/02/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Endocrinology | ||||||
| 11/26/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $48.24 | General |
| Category: Bone Health | ||||||
| 11/26/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $6.00 | General |
| Category: Bone Health | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Exenatide Study of Cardiovascular Event Lowering EXSCEL A Placebo controlled Double blind Trial Examining the Effect of Exenatide QW Treatment on Major Macrovascular Events in Patients with Type 2 Diabetes with Elevated CV Risk | AstraZeneca Pharmaceuticals LP | $39,494 | 2 |
| BAY94 8862 ph 3 conventional in diabetic nephropathy | Bayer HealthCare Pharmaceuticals Inc. | $13.42 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 12,117 | 28,659 | $2.1M | $737,842 |
| 2022 | 37 | 10,061 | 23,282 | $1.7M | $632,287 |
| 2021 | 36 | 9,624 | 21,142 | $1.6M | $587,513 |
| 2020 | 34 | 9,504 | 17,496 | $1.4M | $459,210 |
Total Patients
41,306
Total Services
90,579
Medicare Billing
$2.4M
Procedure Codes
145
All Medicare Procedures & Services
145 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 517 | 1,056 | $246,975 | $115,372 | 46.7% |
| 86769 | Measure of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody | Office | 2023 | 746 | 2,628 | $262,800 | $106,740 | 40.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 57 | 5,700 | $171,000 | $105,292 | 61.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 596 | 827 | $144,725 | $61,946 | 42.8% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 276 | 285 | $85,500 | $27,831 | 32.6% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 763 | 1,339 | $80,340 | $21,811 | 27.1% |
| 84681 | C-peptide (protein) level | Office | 2023 | 540 | 1,024 | $40,960 | $20,718 | 50.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 270 | 633 | $75,960 | $18,807 | 24.8% |
| 84480 | Thyroid hormone, t3 measurement, total | Office | 2023 | 762 | 1,337 | $80,220 | $18,447 | 23.0% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 629 | 1,157 | $69,420 | $16,954 | 24.4% |
| 82746 | Folic acid level, serum | Office | 2023 | 628 | 1,156 | $57,800 | $16,515 | 28.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 38 | 362 | $36,200 | $15,877 | 43.9% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 38 | 336 | $50,400 | $15,371 | 30.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 96 | 96 | $28,800 | $14,160 | 49.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 554 | 1,039 | $51,950 | $13,749 | 26.5% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 271 | 522 | $31,320 | $13,102 | 41.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 795 | 1,439 | $34,536 | $11,903 | 34.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 704 | 1,249 | $67,446 | $11,757 | 17.4% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 84 | 86 | $25,800 | $11,749 | 45.5% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 761 | 1,336 | $80,160 | $11,723 | 14.6% |
| 84270 | Sex hormone binding globulin (protein) level | Office | 2023 | 272 | 522 | $31,320 | $11,035 | 35.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 762 | 1,339 | $32,136 | $10,038 | 31.2% |
| 86800 | Thyroglobulin (thyroid protein) antibody measurement | Office | 2023 | 424 | 635 | $76,200 | $9,853 | 12.9% |
| 86376 | Microsomal antibodies (autoantibody) measurement | Office | 2023 | 426 | 637 | $76,440 | $9,027 | 11.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 59 | $19,175 | $8,220 | 42.9% |
About Dr. Michael Shanik, M.D
Dr. Michael Shanik, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Smithtown, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1386775740.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Shanik, M.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $179,948 received in 2024. These payments were reported across 3,036 transactions from 82 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($982,870).
As a Medicare-enrolled provider, Shanik has provided services to 41,306 Medicare beneficiaries, totaling 90,579 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 145 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Smithtown, NY
- Active Since 03/08/2007
- Last Updated 10/23/2008
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1386775740
Products in Payments
- JARDIANCE (Drug) $195,522
- Ozempic (Drug) $146,063
- MOUNJARO (Drug) $137,675
- Vascepa (Drug) $104,491
- EVENITY (Biological) $80,714
- FreeStyle Libre Pro (Device) $61,659
- Kerendia (Drug) $46,912
- BYETTA (Drug) $39,494
- Prolia (Biological) $36,947
- Livalo (Drug) $32,910
- INVOKANA (Drug) $32,672
- Tresiba (Drug) $31,993
- RYBELSUS (Drug) $31,101
- Victoza (Drug) $27,945
- Rybelsus (Drug) $23,314
- REZDIFFRA (Drug) $17,219
- STEGLATRO (Drug) $16,501
- GVOKE PFS (Drug) $15,744
- GVOKE HYPOPEN (Drug) $14,046
- FREESTYLE LIBRE 3 (Device) $13,531
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Smithtown
Mr. David Kugler, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $270,224
Endocrinology, Diabetes & Metabolism $270,224
Sherry Sussman, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $116,564
Endocrinology, Diabetes & Metabolism $116,564
Mrs. Niti Mohan, Pa, PA
Endocrinology, Diabetes & Metabolism — Payments: $8,416
Endocrinology, Diabetes & Metabolism $8,416
Dr. Deepa Aravind, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $3,289
Endocrinology, Diabetes & Metabolism $3,289
Jessica Kramer, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1,411
Endocrinology, Diabetes & Metabolism $1,411